Commentary

Video

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

Author(s):

Roger Li, MD
Conference|American Urological Association Annual Meeting

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.

Related Videos
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Bernard H. Bochner, MD, FACS
Ana Christina Garrido-Castro, MD
Francisco Hernandez-Ilizaliturri, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD
Kevin Kalinsky, MD, MS
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Related Content
Sundar Jagannath, MBBS, director, the Center of Excellence for Multiple Myeloma, professor, Medicine, Mount Sinai Tisch Cancer Institute
June 7th 2024

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Fernando Cotait Maluf, MD
June 7th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Andrew Kuykendall, MD
October 16th 2023

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

Roger Li, MD
June 6th 2024

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

Ronald C. Chen, MD, MPH, FASCO, FASTRO
June 6th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer